review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1007/S11886-009-0063-3 |
P698 | PubMed publication ID | 19863868 |
P2093 | author name string | George L Bakris | |
Rigas G Kalaitzidis | |||
P2860 | cites work | Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
Prevalence of chronic kidney disease in the United States | Q29614191 | ||
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
Efficacy and safety of benazepril for advanced chronic renal insufficiency | Q33992851 | ||
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis | Q36336393 | ||
Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection | Q36508380 | ||
Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy | Q36596862 | ||
Antihypertensive therapy in the presence of proteinuria | Q36690664 | ||
Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial | Q36891898 | ||
Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review | Q37063760 | ||
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 | ||
Hypertensive nephrosclerosis | Q37137413 | ||
Influence of microalbuminuria in achieving blood pressure goals | Q37241562 | ||
Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study | Q40394575 | ||
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade | Q43279459 | ||
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial | Q44218873 | ||
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis | Q44579295 | ||
Changes in insulin sensitivity, renal function, and markers of endothelial dysfunction in hypertension--the impact of microalbuminuria: a 13-year follow-up study | Q46121987 | ||
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension | Q46169157 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
Renin-angiotensin blockade and kidney disease | Q46426114 | ||
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH | Q46455413 | ||
Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis | Q46555031 | ||
Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria | Q46654200 | ||
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. | Q55043049 | ||
2007 Guidelines for the Management of Arterial Hypertension | Q56970780 | ||
Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial | Q57702534 | ||
Glomerular Filtration Rate, Cardiorenal End Points, and All-Cause Mortality in Type 2 Diabetic Patients | Q58209768 | ||
Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men | Q61684829 | ||
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
Blood pressure and end-stage renal disease in men | Q71574790 | ||
Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study | Q71777734 | ||
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) | Q73499190 | ||
Controversy about COOPERATE ABPM trial data | Q79605302 | ||
Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease | Q79748618 | ||
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease | Q80010742 | ||
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency | Q80313261 | ||
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes | Q80797117 | ||
The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study | Q81454959 | ||
Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease | Q81555894 | ||
P433 | issue | 6 | |
P921 | main subject | arterial hypertension | Q41861 |
P304 | page(s) | 436-442 | |
P577 | publication date | 2009-11-01 | |
P1433 | published in | Current cardiology reports | Q26842345 |
P1476 | title | The current state of RAAS blockade in the treatment of hypertension and proteinuria | |
P478 | volume | 11 |